OSferionBiomaterials

OSferionBiomaterials is a Japan-based orthopedic biomaterials and medical device company focused on the development, manufacture, and sale of bone graft substitutes and implant products. The business originated as Olympus Biomaterial, became Olympus Terumo Biomaterials in 2007 through a joint venture between Olympus and Terumo, and was later transferred to Olympus, then to Polaris Capital Group, before being renamed OSferionBiomaterials in 2025. Its core commercial portfolio includes beta-tricalcium phosphate and hydroxyapatite-based bone void fillers such as OSferion, OSferion60, and BONECERAM, along with orthopedic implants used in knee preservation surgery and cervical laminoplasty. The company operates in the orthopedic field rather than drug development, with emphasis on biomaterials, artificial bone replacement materials, and related surgical products. It is an active commercial-stage medtech company with manufacturing capabilities in Japan.